164 related articles for article (PubMed ID: 20083029)
1. Neuro-oncology: new hope for patients with gliomas.
Deangelis LM
Lancet Neurol; 2010 Jan; 9(1):17-8. PubMed ID: 20083029
[No Abstract] [Full Text] [Related]
2. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
[TBL] [Abstract][Full Text] [Related]
3. Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Schiff D; Purow BW
Nat Rev Neurol; 2009 Jun; 5(6):303-4. PubMed ID: 19498431
[TBL] [Abstract][Full Text] [Related]
4. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?
Labussiere M; Sanson M; Idbaih A; Delattre JY
Oncologist; 2010; 15(2):196-9. PubMed ID: 20133500
[TBL] [Abstract][Full Text] [Related]
5. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
6. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.
Rudà R
Neuro Oncol; 2023 Jan; 25(1):26-27. PubMed ID: 36245275
[No Abstract] [Full Text] [Related]
7. What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski C
Acta Neuropathol; 2013 May; 125(5):621-36. PubMed ID: 23512379
[TBL] [Abstract][Full Text] [Related]
8. From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.
Ferroli P; Acerbi F; Finocchiaro G
World Neurosurg; 2010 Apr; 73(4):234-6. PubMed ID: 20849763
[No Abstract] [Full Text] [Related]
9. On high-risk, low-grade glioma: What distinguishes high from low?
Geurts M; van den Bent MJ
Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
[TBL] [Abstract][Full Text] [Related]
10. Mutant IDH1 and thrombosis in gliomas.
Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
[TBL] [Abstract][Full Text] [Related]
11. Neuro-oncology Treatment Strategies for Primary Glial Tumors.
Santos-Pinheiro F; Graber JJ
Semin Neurol; 2023 Dec; 43(6):889-896. PubMed ID: 38096849
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Gupta R; Webb-Myers R; Flanagan S; Buckland ME
J Clin Pathol; 2011 Oct; 64(10):835-44. PubMed ID: 21752797
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
18. Low-grade glioma.
Kumthekar P; Raizer J; Singh S
Cancer Treat Res; 2015; 163():75-87. PubMed ID: 25468226
[TBL] [Abstract][Full Text] [Related]
19. [Lower-grade Gliomas].
Motomura K
No Shinkei Geka; 2021 May; 49(3):632-639. PubMed ID: 34092569
[TBL] [Abstract][Full Text] [Related]
20. A review of the symptomatic management of malignant gliomas in adults.
Shah U; Morrison T
J Natl Compr Canc Netw; 2013 Apr; 11(4):424-9. PubMed ID: 23584345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]